Frontlight ResearchEarly access
Myeloproliferative neoplasms trials in South Korea
10 trials · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
- Where
- Busan, Jeonju, Seoul, Suwon
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07357727 · EU 2025-523555-66-00 - Phase 1Not yet taking people in South KoreaStudy of INCA036978 in Participants With Myeloproliferative Neoplasms
- Where
- Jongno-gu, Seoul, Seocho-gu, Seoul
- Age
- 18 years and over
- People
- 218 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07441694 · EU 2026-525217-31-00 - Phase 3Not yet taking people in South KoreaA Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
- Where
- Busan, Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 426 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07623200 · EU 2026-525398-38-00 - Phase 4Taking peopleAsciminib Roll-over Study
- Where
- Busan, Jeollanam, Seoul, Uijeongbu-si
- Age
- 7 years to 100 years
- People
- 347 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00 - Phase 3Not yet taking people in South KoreaA Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Where
- Daegu, Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 324 worldwide
- Run by
- Takeda
See details and how to joinNCT07623161 · EU 2026-525660-17-00 - Phase 1/2Taking peopleA Study of BGB-11417 in Participants With Myeloid Malignancies
- Where
- GangnamGu, SeodaemunGu
- Age
- 18 years and over
- People
- 260 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT04771130 · EU 2023-508881-14-00 - Phase 2Taking peopleA Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- Where
- Busan, Seocho, Seoul
- Age
- 18 years and over
- People
- 58 worldwide
- Run by
- Karyopharm Therapeutics Inc
See details and how to joinNCT05980806 - Phase 2Taking peopleA Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis
- Where
- Incheon, Seoul
- Age
- 18 years and over
- People
- 135 worldwide
- Run by
- Takeda
See details and how to joinNCT05037760 · EU 2023-507468-38-00 - Phase 3Taking peopleStudy of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Where
- Busan, Daegu, Seoul
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Kartos Therapeutics, Inc.
See details and how to joinNCT06479135 - No phaseTaking peopleA Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis
- Where
- Seoul
- Age
- 19 years and over
- People
- 137
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06073847